Alpha Cognition (ACOG) Restructuring Costs (2023 - 2024)
Alpha Cognition's (ACOG) quarterly Restructuring Costs came in at $11779.0 in Q4 2024, down 83.51% year-on-year from $71448.0 in Q1 2024, and up 162.03% quarter-over-quarter from -$18990.0 in Q3 2024.
Alpha Cognition (ACOG) Restructuring Costs (2023 - 2024) Analysis & Trends
Alpha Cognition's Restructuring Costs history runs 2 years deep, the most recent figure standing at $11779.0 for Q4 2024.
- On a quarterly basis, Restructuring Costs fell 83.51% year-over-year to $11779.0 in Q4 2024; TTM through Dec 2024 was $66892.0, a N/A change from a year earlier, with the FY2024 full-year figure at $16160.0, down 78.69% from the prior year.
- Restructuring Costs improved to $11779.0 in Q4 2024 per ACOG's latest filing, from -$18990.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $71448.0 in Q4 2023 and bottomed at -$18990.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alpha Cognition | 145.51 Mn | 79.41 Mn | 2.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 11,779.00 |
| Sep 30, 2024 | -18,990.00 |
| Dec 31, 2023 | 71,448.00 |
| Sep 30, 2023 | 2,655.00 |